| 0.52 0.133 (34.26%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.39 | 1-year : | 1.98 |
| Resists | First : | 1.19 | Second : | 1.7 |
| Pivot price | 1.12  |
|||
| Supports | First : | 0.37 | Second : | 0.3 |
| MAs | MA(5) : | 0.88 |
MA(20) : | 1.1 |
| MA(100) : | 1.7 |
MA(250) : | 2.59 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.9 |
D(3) : | 23.5 |
| RSI | RSI(14): 29.9  |
|||
| 52-week | High : | 8.93 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MDCX ] has closed above bottom band by 3.8%. Bollinger Bands are 187.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.6 - 0.61 | 0.61 - 0.61 |
| Low: | 0.36 - 0.37 | 0.37 - 0.37 |
| Close: | 0.38 - 0.39 | 0.39 - 0.39 |
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
Mon, 09 Mar 2026
SkinJect cancer patch clears 3 in 4 lesions in trial, may spare surgery - Stock Titan
Fri, 06 Mar 2026
Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture - TipRanks
Thu, 05 Mar 2026
Microneedle skin cancer patch shows 73% clearance in Medicus trial - Stock Titan
Wed, 04 Mar 2026
Medicus Pharma on Bloomberg World - The Providence Journal
Tue, 03 Mar 2026
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Ellwood City Ledger
Tue, 30 Dec 2025
Medicus Pharma Launches At-the-Market Equity Offering Program - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 1.483e+007 (%) |
| Held by Institutions | 28.9 (%) |
| Shares Short | 889 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -170.7 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 25.29 |
| Dividend | 0 |
| Forward Dividend | 1.04e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|